AR035963A1 - Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion - Google Patents

Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion

Info

Publication number
AR035963A1
AR035963A1 ARP020101575A ARP020101575A AR035963A1 AR 035963 A1 AR035963 A1 AR 035963A1 AR P020101575 A ARP020101575 A AR P020101575A AR P020101575 A ARP020101575 A AR P020101575A AR 035963 A1 AR035963 A1 AR 035963A1
Authority
AR
Argentina
Prior art keywords
useful
intermediates
procedures
preparation
inhibitors
Prior art date
Application number
ARP020101575A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR035963A1 publication Critical patent/AR035963A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Los compuestos derivados de trifluormetilbenceno son de fórmulas (1), (2), (3) y (4) en la que R se selecciona de metilo, bencilo y bencilo sustituido. También se dan a conocer los procedimientos para su preparación. Estos compuestos son útiles como intermediarios de inhibidores de la proteína de transferencia del éster de colesterilo, útiles para tratar a sujetos cuyo perfil lipídico constituye un mayor riesgo de enfermedad cardíaca coronaria.
ARP020101575A 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion AR035963A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
AR035963A1 true AR035963A1 (es) 2004-07-28

Family

ID=23103272

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP020101575A AR035963A1 (es) 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion
ARP020101576A AR036331A1 (es) 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
ARP040102071A AR044706A2 (es) 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP020101576A AR036331A1 (es) 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
ARP040102071A AR044706A2 (es) 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Country Status (25)

Country Link
US (3) US6689897B2 (es)
EP (2) EP1383734B1 (es)
JP (2) JP3924251B2 (es)
KR (2) KR100639745B1 (es)
CN (3) CN100357265C (es)
AR (3) AR035963A1 (es)
AT (2) ATE316957T1 (es)
AU (1) AU2002253448B2 (es)
BR (2) BR0209238A (es)
CA (2) CA2445623A1 (es)
CZ (2) CZ20032900A3 (es)
DE (2) DE60209004T2 (es)
DK (2) DK1425270T3 (es)
ES (2) ES2259080T3 (es)
HK (1) HK1062294A1 (es)
HU (2) HU225777B1 (es)
IL (2) IL157546A0 (es)
MX (2) MXPA03009936A (es)
PL (2) PL366584A1 (es)
PT (1) PT1425270E (es)
RU (2) RU2265010C2 (es)
TW (1) TWI250974B (es)
WO (2) WO2002088069A2 (es)
YU (2) YU84403A (es)
ZA (2) ZA200306600B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1556047A4 (en) * 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2004056358A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
EP1594843B1 (en) * 2003-02-18 2013-05-22 Takasago International Corporation METHOD FOR PRODUCING AN OPTICALLY ACTIVE beta-amino acid derivative
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
CA2515789A1 (en) * 2003-03-17 2004-09-30 Kaneka Corporation Method for producing(r)-3-[4-(trifluoromethyl)phenylamino]-pentanoic acid amide derivative
CA2554982A1 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
ATE442358T1 (de) * 2003-10-08 2009-09-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
WO2005046662A2 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
MXPA06011540A (es) * 2004-04-07 2007-01-26 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
MX2007016093A (es) * 2005-06-20 2008-03-10 Astrazeneca Ab Proceso para la produccion de sulfonatos de (alcoxicarbonilamino)- alquilo.
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
MX342104B (es) 2011-04-12 2016-09-13 Chong Kun Dang Pharmaceutical Corp Derivados de cicloalquenil arilo para inhibidor de cetp.
TWI627167B (zh) * 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
MX2015009851A (es) 2013-01-31 2015-10-14 Chong Kun Dang Pharm Corp Compuestos derivados de ciclohexeno sustituidos con biarilos o biarilos heterociclicos como inhibidores de cetp.
JP2016535726A (ja) * 2013-11-11 2016-11-17 ロンザ・リミテッド ルイス酸を用いて第１３族のシアノ化合物を調製するための方法
ES2926775T3 (es) * 2014-08-12 2022-10-28 Newamsterdam Pharma B V Proceso de preparación de intermedios sintéticos para la preparación de derivados de tetrahidroquinolina
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1097158B1 (en) 1998-07-10 2006-01-25 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.

Also Published As

Publication number Publication date
JP2004527556A (ja) 2004-09-09
KR100639745B1 (ko) 2006-10-30
MXPA03009935A (es) 2004-01-29
US6600045B2 (en) 2003-07-29
EP1425270A2 (en) 2004-06-09
HUP0304041A2 (hu) 2004-04-28
CN1680292A (zh) 2005-10-12
ZA200306600B (en) 2004-08-25
US6689897B2 (en) 2004-02-10
CZ20032900A3 (cs) 2004-06-16
CN1505609A (zh) 2004-06-16
RU2265010C2 (ru) 2005-11-27
IL157544A0 (en) 2004-03-28
WO2002088085A3 (en) 2004-03-25
ES2259080T3 (es) 2006-09-16
DE60210265D1 (de) 2006-05-18
JP3924251B2 (ja) 2007-06-06
EP1383734B1 (en) 2006-02-01
RU2003131871A (ru) 2005-04-10
ATE321755T1 (de) 2006-04-15
CZ20032898A3 (cs) 2004-07-14
CN1297541C (zh) 2007-01-31
AR044706A2 (es) 2005-09-21
IL157546A0 (en) 2004-03-28
RU2003131870A (ru) 2005-01-27
CN100357265C (zh) 2007-12-26
CA2445623A1 (en) 2002-11-07
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
US20030216576A1 (en) 2003-11-20
CA2445693A1 (en) 2002-11-07
HK1062294A1 (en) 2004-10-29
CN1529696A (zh) 2004-09-15
CN1267411C (zh) 2006-08-02
WO2002088069A2 (en) 2002-11-07
DK1425270T3 (da) 2006-07-03
ZA200306599B (en) 2004-10-22
ES2256461T3 (es) 2006-07-16
KR100591998B1 (ko) 2006-06-22
WO2002088085A2 (en) 2002-11-07
WO2002088069A9 (en) 2003-12-04
BR0209291A (pt) 2004-07-13
EP1425270B1 (en) 2006-03-29
US6706881B2 (en) 2004-03-16
TWI250974B (en) 2006-03-11
JP3924250B2 (ja) 2007-06-06
HU225777B1 (en) 2007-08-28
US20020177716A1 (en) 2002-11-28
PT1425270E (pt) 2006-07-31
HUP0304039A3 (en) 2005-10-28
PL366700A1 (en) 2005-02-07
DE60209004T2 (de) 2006-09-28
DE60209004D1 (de) 2006-04-13
HUP0304041A3 (en) 2005-08-29
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
YU84403A (sh) 2006-08-17
MXPA03009936A (es) 2004-01-29
ATE316957T1 (de) 2006-02-15
KR20040015200A (ko) 2004-02-18
EP1383734A2 (en) 2004-01-28
PL366584A1 (en) 2005-02-07
US20030073843A1 (en) 2003-04-17
DE60210265T2 (de) 2006-10-12
DK1383734T3 (da) 2006-05-15
WO2002088069A3 (en) 2003-02-20
YU84303A (sh) 2006-05-25
JP2004531541A (ja) 2004-10-14
AU2002253448B2 (en) 2007-07-05
HUP0304039A2 (hu) 2004-03-29

Similar Documents

Publication Publication Date Title
AR035963A1 (es) Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
ES2172670T3 (es) Pirrolpirimidinas y procedimientos para su preparacion.
DK1038022T3 (da) Evaluering af humane papillomavirus-tilknyttede sygdomme
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
GT199800158A (es) Agonistas de prostaglandinas.
ES2037013T3 (es) Procedimiento para preparar tieno-1,4-diazepinas.
ECSP055681A (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
AR005987A1 (es) Terapia combinada para la osteoporosis
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
MA27991A1 (fr) Derives d'aminoquinoline et leur utilisation comme ligands d'adenosine a3
ES2150808T3 (es) Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
ES2155621T3 (es) Derivados azo del acido 5-aminosalicilico para el tratamiento de la enfermedad inflamatoria intestinal.
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
ES2164765T3 (es) Heterociclilbenzonitrilos.
AR008781A1 (es) Compuestos de furano nitrona
ECSP003590A (es) Compuestos calcioliticos
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
PT762883E (pt) Piridilbisfosfonatos utilizaveis como agentes terapeuticos
ATE428429T1 (de) Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis
DK0877631T3 (da) Konjugat af albumin og et xanthen-farvestof til differentiering mellem sygdomsramt og sundt væv
ES2185935T3 (es) Compuestos antioxidantes.
AR010452A1 (es) Derivados del acido 2-iminooxifenilacetico, procedimiento y productos intermedios para su obtencion, el uso de los mismos, las composiciones paracontrolar animales u hongos nocivos que contienen dichos derivados y el procedimiento para controlar hongos y animales nocivos con dichos derivados.
IT1290828B1 (it) Uso di proteine estraibili da organi animali per la preparazione di medicamenti per il trattamento di condizioni patologiche

Legal Events

Date Code Title Description
FB Suspension of granting procedure